Arrail Group Limited announces its annual results for the financial year ended 31 March 2025, reporting revenue of approximately RMB 1.746 billion and operating profit of RMB 36.2 million. Revenue compares with RMB 1.688 billion in the prior year, while operating profit rises 39.4 percent year on year.
Arrail Group says its restricted shares begin circulating on 22 September 2022, while founder Zou Qifang and major pre-IPO investors Qiming Venture Partners and Temasek commit not to reduce their holdings. The company reports FY2021/22 revenue of RMB1.624 billion and 1.559 million patient visits.
Arrail Group, a China dental services provider, lists on the main board of the Hong Kong Stock Exchange at HK$14.62 per share. Qiming Venture Partners says it first invested in Arrail in 2010 and participated in the company's Series A, B, and C rounds.
Kirkland & Ellis represents Arrail Group Limited in its global offering and main-board listing on the Hong Kong Stock Exchange, completed on March 22, 2022. Arrail, listed as HKSE: 6639, is identified as the largest dental services provider by revenue in China’s premium private dental services market.
Arrail Group, one of China’s largest dental services providers, is weighing a Hong Kong or New York listing as it plans a nationwide expansion. Founder and chairman Robert Zou Qifang says the expansion targets about 1,000 clinics and would require roughly 5 billion yuan over seven years.